Search

During the AseBio Investor Day, held on May 15th in San Sebastián, AseBio has revealed data on private financing collected in the AseBio 2023 Report.

Oryzon Genomics will attend and participate, both as speaker and guest, in different events related to biotechnology and investment.

Hector Olabegogeaskoetxea Narbaiza, CEO of MONDRAGON Health, Silver Sponsor of AseBio Investor Day, analyzes the biotech innovation ecosystem in Spain.

Companies connected to the Barcelona Science Park received €85.4 million in 2023, 38.6% of the total funding in the BioRegion of Catalonia, €220 million, according to the BioRegion of Catalonia Report

Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) Company planning to request an End-of-Phase II meeting with the FDA to discuss plans

Meet Appliant, our new member. We talked to its Marc Ramoneda, Partner & CEO.

We analyze the challenges that biotechnology companies face in terms of financing, with David Roberto García, Chief Financial Officer of Laminar Pharma, Silver Sponsor of AseBio Investor Day 2024.

We interviewed Roger Pique, General Partner at Inveready, Bronze Sponsor of the AseBio Investor Day 2024.

BIOFISH 7000 SAL is a unique device because it is connected to the cloud, faster, more accurate, versatile in the sample to be measured, and quantifies salt by measuring sodium, a real factor of

The Biscayan biopharmaceutical company, which plans to launch its first biological medicine into the market in the first half of 2025, will use the funds to expand its manufacturing capacity and

The main objective of the project is the creation of innovative in vitro models using microencapsulation of human liver cells by means of bioprinting systems.

In addition to this rating, earlier this year, CDP recognized the company for its transparency and efforts against climate change.

The conference held in Switzerland is one of Europe's benchmark events in the biotechnology sector, attracting professionals from the global life sciences community.

Immunobiogram is an in vitro diagnostic device that allows physicians to optimize immunosuppressive therapy on an individualized basis in renal transplant patients.

Ane Insausti, Deputy for Economic Promotion and Strategic Projects of the Provincial Council of Gipuzkoa, analyzes the commitment of the Basque Country to innovation and biotechnology.

The company has also announced that its launch is coming soon.

Biotechnology has achieved significant advances in diagnosis and precision therapies, the production of biotechnological drugs, and the treatment and understanding of infectious, autoimmune, and